細胞治療技術市場:治療タイプ別(自己由来、同種異系)、治療領域別(癌、CVD、皮膚科)、地域別 - 2030年までの世界予測Cell Therapy Technologies Market based on By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region - Global Forecast up to 2030 細胞治療は、HIV/AIDS、癌、感染症など様々な疾患の診断や予後の情報を与える上で重要である。研究者や医療従事者が、新しい細胞ベースの技術を用いて、病気の原因、病気の発症、治療反応に関する洞察を得るのに... もっと見る
サマリー細胞治療は、HIV/AIDS、癌、感染症など様々な疾患の診断や予後の情報を与える上で重要である。研究者や医療従事者が、新しい細胞ベースの技術を用いて、病気の原因、病気の発症、治療反応に関する洞察を得るのに役立っている。世界的な人口増加、気候変動、ヒトと動物の相互作用の増大は、新たなウイルス流行の発生を助長する環境を生み出している。細胞治療の研究と応用は、診断ツールの強化、治療アプローチ、病気の原因に関するより良い知識を提供するため、これらの問題に取り組む上で極めて重要である。細胞生物学研究は、主に幹細胞治療や遺伝子治療といった新薬の開発に関係している。信頼性の高い知見を得るためには、高品質のツール、試薬、関連商品が必要です。一方、細胞生物学研究では、規制規則を満たし、厳しい品質基準を維持するためには、かなりの費用がかかります。資金に限りのある研究機関や中小企業にとっては、高価な研究用製品を入手できない可能性があり、問題となります。 プレシジョン・メディシン(精密医療)とは、遺伝的要因、環境要因、生活習慣要因を考慮した、病気の治療と予防のための発展途上のアプローチである。患者一人ひとりの状態や病歴に応じて薬剤を選択することが必要となる。腫瘍学は、その使用が多様な疾患に拡大する中でも、精密医療において著しい進歩を遂げてきた。診断、治療、予防に対するこの個別化アプローチは、遺伝、環境、ライフスタイルなどの患者情報をフルに活用することで、より適切な判断を下す。 本調査のセグメンテーション範囲は以下の通り。 治療タイプに基づく細胞治療技術市場 - 同種療法 o 幹細胞治療 造血幹細胞療法 間葉系幹細胞療法 o 非幹細胞療法 ケラチノサイトおよび線維芽細胞を用いた治療法 その他 - 自家療法 o 幹細胞治療 BM、血液、臍帯由来幹細胞 脂肪由来細胞 その他 o 非幹細胞療法 T細胞療法 CAR T細胞療法 T細胞受容体(TCR)ベース 治療領域に基づく細胞治療技術市場 - 腫瘍学 - 心血管疾患(CVD) - 筋骨格系疾患 - 皮膚科学 - その他 地域別細胞治療技術市場 - 北米 米国 カナダ - 欧州 o ドイツ o イギリス o フランス o イタリア o スペイン o 残りのヨーロッパ(RoE) - アジア太平洋(APAC) o 中国 o 日本 o インド o オーストラリア o 韓国 o その他のアジア太平洋地域(RoAPAC) - ラテンアメリカ(LATAM) o ブラジル o アルゼンチン o その他の南米地域 - 中東・アフリカ(MEA) o アラブ首長国連邦 o トルコ o サウジアラビア o 南アフリカ o その他の中東・アフリカ 細胞の種類別では、幹細胞分野が2019年の世界の細胞治療市場をリードしており、政府のさまざまなイニシアチブの結果として人気を集めていることから、この傾向は予測期間中も続くと予想される。幹細胞バンクの数は発展途上国で増加しており、これが細胞治療産業の拡大に拍車をかけている。さらに、幹細胞の保存に関する理解の高まりは、細胞治療市場の成長に有益な影響を与えている。さらに、2019年は同種療法分野が市場を支配した。この治療法は、自分自身の免疫幹細胞の生成を含み、高用量の細胞毒性薬による治療を生き延びたがん細胞を破壊することができるため、好ましい。 自家療法と同種療法に分けられる。市場は、悪性腫瘍、筋骨格系疾患、自己免疫疾患、皮膚科などの治療分野別に分けられる。エンドユーザーは、病院・診療所と学術・研究機関の2種類に分けられる。市場は4つの地域に分けられる:北米(米国、カナダ、メキシコ)、欧州(ドイツ、英国、フランス、スペイン、イタリア、その他欧州)、アジア太平洋(日本、中国、インド、オーストラリア、その他アジア太平洋)、LAMEA(ブラジル、南アフリカ、サウジアラビア、その他LAMEA)である。 病院とクリニックのカテゴリーは、予測期間を通じて最も速いCAGRで発展すると予想されている。同分野の収益性の高い拡大は、ここ数年のパイプライン開発件数の増加と関連している可能性がある。CRIによると、細胞治療プロジェクトの数は2018年の753から2019年には1,011に上昇した。 人口の増加、老年人口の増加、慢性疾患管理におけるこれらの治療法の可能性に関する医療機関や患者の意識の高まりにより、アジア太平洋地域は細胞治療市場で事業を展開する主要企業にとって有利な機会を提供している。さらに、医療費の増加とガイドラインの策定が、この地域での市場拡大を促進すると予測されている。 Kolon Tissue Gene, Inc.、Osiris Therapeutics, Inc.、JCR Pharmaceuticals Co.Ltd.、NuVasive, Inc.、Stemedica Cell Technologies, Inc.、Cells for Cells、Holostem Terapie Avanzate S.r.l.、Mesoblast Ltd.、Medipost Co.Ltd.などが、世界の細胞療法市場で事業を展開している大手企業です。 - 本レポートは、細胞治療技術市場の最も重要な属性を示しており、これが市場を牽引し、機会を提供しています。 - この調査レポートは、細胞治療技術市場の成長を市場のいくつかのセグメントに基づいて詳細に分析します。 - 細胞治療技術市場の過去と現在の動向予測を提示します。 - また、細胞治療技術市場の主要企業の主要戦略や能力などの競争分析も提示しています。 目次Table of Contents1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Therapy Type: Market Size & Analysis 5.1. Overview 5.2. Allogeneic Therapies 5.3. Autologous Therapies 6. Therapeutic Area: Market Size & Analysis 6.1. Overview 6.2. Oncology 6.3. Cardiovascular Disease (CVD) 6.4. Musculoskeletal Disorders 6.5. Dermatology 6.6. Others 7. Geography: Market Size & Analysis 7.1. Overview 7.2. North America (U.S., Mexico, Canada) 7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 7.5. Latin America (Brazil, Argentina) 7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 8. Competitive Landscape 8.1. Competitor Comparison Analysis 8.2. Market Developments 8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 8.2.2. Product Launches and execution 9. Vendor Profiles 9.1. Novartis AG 9.1.1. Overview 9.1.2. Financial Overview 9.1.3. Product Offerings 9.1.4. Developments 9.1.5. Business Strategy 9.2. Gilead Sciences, Inc. 9.2.1. Overview 9.2.2. Financial Overview 9.2.3. Product Offerings 9.2.4. Developments 9.2.5. Business Strategy 9.3. Bristol-Myers Squibb Company 9.3.1. Overview 9.3.2. Financial Overview 9.3.3. Product Offerings 9.3.4. Developments 9.3.5. Business Strategy 9.4. Johnson & Johnson Services, Inc 9.4.1. Overview 9.4.2. Financial Overview 9.4.3. Product Offerings 9.4.4. Developments 9.4.5. Business Strategy 9.5. JCR Pharmaceuticals Co., Ltd. 9.5.1. Overview 9.5.2. Financial Overview 9.5.3. Product Offerings 9.5.4. Developments 9.5.5. Business Strategy 9.6. Tego Science 9.6.1. Overview 9.6.2. Financial Overview 9.6.3. Product Offerings 9.6.4. Developments 9.6.5. Business Strategy 9.7. Atara Biotherapeutics 9.7.1. Overview 9.7.2. Financial Overview 9.7.3. Product Offerings 9.7.4. Developments 9.7.5. Business Strategy 9.8. Takeda Pharmaceutical Company Limited 9.8.1. Overview 9.8.2. Financial Overview 9.8.3. Product Offerings 9.8.4. Developments 9.8.5. Business Strategy 9.9. Bluebird Bio, Inc. 9.9.1. Overview 9.9.2. Financial Overview 9.9.3. Product Offerings 9.9.4. Developments 9.9.5. Business Strategy 9.10. Dendreon Corp. 9.10.1. Overview 9.10.2. Financial Overview 9.10.3. Product Offerings 9.10.4. Developments 9.10.5. Business Strategy 10. Analyst Opinion 11. Annexure 11.1. Report Scope 11.2. Market Definitions 11.3. Research Methodology 11.3.1. Data Collation and In-house Estimation 11.3.2. Market Triangulation 11.3.3. Forecasting 11.4. Report Assumptions 11.5. Declarations 11.6. Stakeholders 11.7. Abbreviations 図表リストTablesTABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION) TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 82. NOVARTIS AG: FINANCIALS TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS TABLE 97. TEGO SCIENCE: FINANCIALS TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS TABLE 109. DENDREON CORP.: FINANCIALS TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS
SummaryCell therapy is important in giving diagnostic and prognostic information for a variety of disorders, including HIV/AIDS, cancer, and infectious diseases. It helps academics and healthcare practitioners to acquire insights into disease causes, illness development, and therapy responses using novel cellular-based techniques. Global population expansion, climate change, and greater human-animal interaction have produced an environment conducive to the genesis of novel viral epidemics. Cell therapy research and applications are critical in tackling these issues because they provide enhanced diagnostic tools, therapeutic approaches, and a better knowledge of disease causes. Table of ContentsTable of Contents1. Executive Summary 2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends 3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.2.1. Porter Five Forces 3.3. Related Markets 4. Market characteristics 4.1. Market Overview 4.2. Market Segmentation 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. DRO - Impact Analysis 5. Therapy Type: Market Size & Analysis 5.1. Overview 5.2. Allogeneic Therapies 5.3. Autologous Therapies 6. Therapeutic Area: Market Size & Analysis 6.1. Overview 6.2. Oncology 6.3. Cardiovascular Disease (CVD) 6.4. Musculoskeletal Disorders 6.5. Dermatology 6.6. Others 7. Geography: Market Size & Analysis 7.1. Overview 7.2. North America (U.S., Mexico, Canada) 7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe) 7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC) 7.5. Latin America (Brazil, Argentina) 7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa) 8. Competitive Landscape 8.1. Competitor Comparison Analysis 8.2. Market Developments 8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships 8.2.2. Product Launches and execution 9. Vendor Profiles 9.1. Novartis AG 9.1.1. Overview 9.1.2. Financial Overview 9.1.3. Product Offerings 9.1.4. Developments 9.1.5. Business Strategy 9.2. Gilead Sciences, Inc. 9.2.1. Overview 9.2.2. Financial Overview 9.2.3. Product Offerings 9.2.4. Developments 9.2.5. Business Strategy 9.3. Bristol-Myers Squibb Company 9.3.1. Overview 9.3.2. Financial Overview 9.3.3. Product Offerings 9.3.4. Developments 9.3.5. Business Strategy 9.4. Johnson & Johnson Services, Inc 9.4.1. Overview 9.4.2. Financial Overview 9.4.3. Product Offerings 9.4.4. Developments 9.4.5. Business Strategy 9.5. JCR Pharmaceuticals Co., Ltd. 9.5.1. Overview 9.5.2. Financial Overview 9.5.3. Product Offerings 9.5.4. Developments 9.5.5. Business Strategy 9.6. Tego Science 9.6.1. Overview 9.6.2. Financial Overview 9.6.3. Product Offerings 9.6.4. Developments 9.6.5. Business Strategy 9.7. Atara Biotherapeutics 9.7.1. Overview 9.7.2. Financial Overview 9.7.3. Product Offerings 9.7.4. Developments 9.7.5. Business Strategy 9.8. Takeda Pharmaceutical Company Limited 9.8.1. Overview 9.8.2. Financial Overview 9.8.3. Product Offerings 9.8.4. Developments 9.8.5. Business Strategy 9.9. Bluebird Bio, Inc. 9.9.1. Overview 9.9.2. Financial Overview 9.9.3. Product Offerings 9.9.4. Developments 9.9.5. Business Strategy 9.10. Dendreon Corp. 9.10.1. Overview 9.10.2. Financial Overview 9.10.3. Product Offerings 9.10.4. Developments 9.10.5. Business Strategy 10. Analyst Opinion 11. Annexure 11.1. Report Scope 11.2. Market Definitions 11.3. Research Methodology 11.3.1. Data Collation and In-house Estimation 11.3.2. Market Triangulation 11.3.3. Forecasting 11.4. Report Assumptions 11.5. Declarations 11.6. Stakeholders 11.7. Abbreviations List of Tables/GraphsTablesTABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION) TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION) TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION) TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION) TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION) TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION) TABLE 82. NOVARTIS AG: FINANCIALS TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS TABLE 97. TEGO SCIENCE: FINANCIALS TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS TABLE 109. DENDREON CORP.: FINANCIALS TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
IHR Insights社の医療分野での最新刊レポート
本レポートと同じKEY WORD(dermatology)の最新刊レポート
よくあるご質問IHR Insights社はどのような調査会社ですか?IHR InsightsはICT、化学品、ヘルスケア、半導体など、世界の幅広い分野を対象に調査し、専門的な知識を基に市場調査報告書を出版しています。 主な調査分野 ◇ICT ◇化学品、材料、... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |